Cocrystal Pharma Inc Stock OTC Bulletin Board
Stocks
US19188J1025
Biotechnology & Medical Research
| Market Cap | 20.42M 17.66M 16.49M 15.13M 28.46M 1.94B 28.91M 193M 75.95M 974M 76.67M 74.99M 3.22B | P/E 2026 * |
-1.55x | P/E 2027 * | -1.66x |
|---|---|---|---|---|---|
| Enterprise Value | 20.42M 17.66M 16.49M 15.13M 28.46M 1.94B 28.91M 193M 75.95M 974M 76.67M 74.99M 3.22B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
77.62% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -6.38% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Sapirstein
CEO | Chief Executive Officer | 64 | 2026-06-02 |
James Martin
CEO | Chief Executive Officer | 59 | 2021-05-26 |
Sam Lee
CEO | Chief Executive Officer | 66 | 2021-05-26 |
| Director | Title | Age | Since |
|---|---|---|---|
Phillip Frost
BRD | Director/Board Member | 89 | 2014-01-01 |
Roger Kornberg
CHM | Chairman | 79 | 2021-05-26 |
Steven Rubin
BRD | Director/Board Member | 65 | 2014-01-01 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.38% | -6.38% | - | - | 20.42M | |
| +8.49% | +20.55% | +70.77% | +110.32% | 68.12B | |
| +1.25% | +2.44% | +34.27% | +70.43% | 55.18B | |
| -1.09% | +32.96% | +19.67% | +494.56% | 28.63B | |
| +10.83% | +18.38% | +56.20% | +6.03% | 23.99B | |
| +2.72% | +3.41% | -16.11% | -7.96% | 23.53B | |
| +6.50% | +7.56% | +44.65% | -21.73% | 18.45B | |
| +6.20% | +11.51% | +33.87% | +693.38% | 16.44B | |
| -3.88% | +16.98% | +199.30% | +359.77% | 15.83B | |
| +3.58% | +1.96% | +43.35% | +163.76% | 13.4B | |
| Average | +2.82% | +11.68% | +54.00% | +207.62% | 29.28B | |
| Weighted average by Cap. | +4.36% | +13.10% | +50.69% | +168.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -10.5M -9.08M -8.48M -7.78M -14.63M -999M -14.87M -99.51M -39.06M -501M -39.43M -38.57M -1.66B | -11.5M -9.95M -9.29M -8.52M -16.03M -1.09B -16.28M -109M -42.78M -549M -43.18M -42.24M -1.81B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
